{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,17]],"date-time":"2026-02-17T13:24:00Z","timestamp":1771334640382,"version":"3.50.1"},"reference-count":35,"publisher":"Oxford University Press (OUP)","issue":"1205","license":[{"start":{"date-parts":[[2025,9,29]],"date-time":"2025-09-29T00:00:00Z","timestamp":1759104000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/pages\/standard-publication-reuse-rights"}],"funder":[{"name":"Construction Project","award":["TJWJ2022XK013"],"award-info":[{"award-number":["TJWJ2022XK013"]}]},{"name":"Tianjin Key Medical Discipline","award":["TJYXZDXK-029A"],"award-info":[{"award-number":["TJYXZDXK-029A"]}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82170327"],"award-info":[{"award-number":["82170327"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82370332"],"award-info":[{"award-number":["82370332"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2026,2,13]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>New-onset atrial fibrillation (AF) in the setting of acute myocardial infarction (AMI) is associated with higher risks of stroke and mortality. However, current guidelines lack specific antithrombotic recommendations for this population. This study aimed to explore the association between rivaroxaban and the prognosis of patients with AMI and new-onset AF.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>This retrospective cohort study included patients with AMI and new-onset AF receiving dual antiplatelet therapy between August 2016 and June 2023 in Tianjin, China. New-onset AF (transient or nontransient) was defined as the first diagnosis of AF following AMI. The primary outcome was stroke.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>2477 patients were identified, including 141 rivaroxaban users and 2336 patients without oral anticoagulants (OAC). Over a median follow-up of 922 days, rivaroxaban users had a 5.7% lower risk of stroke than non-OAC users, although this was not statistically significant (19.9% vs. 25.6%; P\u2009=\u2009.152). Despite the suggestion of a protective trend, multivariable Cox regression showed that rivaroxaban use was not associated with a lower risk of stroke (hazard ratio, 0.77; 95% confidence interval, 0.52\u20131.13, P\u2009=\u2009.187). After propensity score matching, 155 transient (rivaroxaban: 42; non-OAC: 113) and 295 nontransient AF patients (rivaroxaban: 85; non-OAC: 210) were included. No significant association was observed between rivaroxaban and stroke, ischemic stroke, hemorrhagic stroke, all-cause mortality, cardiovascular mortality, bleeding, or major bleeding.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>No significant association was observed between rivaroxaban and clinical outcomes in patients with AMI and new-onset AF. Given the small sample size and limited statistical power, the findings are exploratory and require further validation.<\/jats:p>\n                    <jats:p>Key messages \u2002What is already known on this topic: Evidence from previous studies indicates that acute myocardial infarction (AMI) patients with new-onset atrial fibrillation (AF) are associated with higher risks of ischemic stroke and mortality. However, the association between rivaroxaban and the prognosis of patients with AMI and new-onset AF remains uncertain. \u2002What this study adds: Among patients with AMI and new-onset AF receiving dual antiplatelet therapy, no significant differences were observed between rivaroxaban users and non-oral anticoagulant users in terms of the risks of stroke, ischemic stroke, hemorrhagic stroke, all-cause mortality, cardiovascular mortality, bleeding, or major bleeding. However, these results should be interpreted with caution due to the small sample size and limited statistical power of the study. \u2002How this study might affect research, practice or policy: Future prospective large-scale studies and randomized controlled trials are needed to further examine the role of rivaroxaban and other types of oral anticoagulants in patients with AMI and new-onset AF.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1093\/postmj\/qgaf163","type":"journal-article","created":{"date-parts":[[2025,9,12]],"date-time":"2025-09-12T11:53:38Z","timestamp":1757678018000},"page":"271-282","source":"Crossref","is-referenced-by-count":0,"title":["Association between rivaroxaban and the prognosis of patients with acute myocardial infarction and new-onset atrial fibrillation"],"prefix":"10.1093","volume":"102","author":[{"given":"Yi","family":"Zheng","sequence":"first","affiliation":[{"name":"Tianjin Key Laboratory of Ionic-Molecular Function of Cardiovascular Disease, Department of Cardiology, Tianjin Institute of Cardiology, Second Hospital of Tianjin Medical University , No. 23, Pingjiang Road, Hexi District, Tianjin 300211 ,","place":["China"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ying","family":"Liu","sequence":"additional","affiliation":[{"name":"Tianjin Key Laboratory of Ionic-Molecular Function of Cardiovascular Disease, Department of Cardiology, Tianjin Institute of Cardiology, Second Hospital of Tianjin Medical University , No. 23, Pingjiang Road, Hexi District, Tianjin 300211 ,","place":["China"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xinyu","family":"Zheng","sequence":"additional","affiliation":[{"name":"Tianjin Key Laboratory of Ionic-Molecular Function of Cardiovascular Disease, Department of Cardiology, Tianjin Institute of Cardiology, Second Hospital of Tianjin Medical University , No. 23, Pingjiang Road, Hexi District, Tianjin 300211 ,","place":["China"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5510-1253","authenticated-orcid":false,"given":"Gary","family":"Tse","sequence":"additional","affiliation":[{"name":"Tianjin Key Laboratory of Ionic-Molecular Function of Cardiovascular Disease, Department of Cardiology, Tianjin Institute of Cardiology, Second Hospital of Tianjin Medical University , No. 23, Pingjiang Road, Hexi District, Tianjin 300211 ,","place":["China"]},{"name":"School of Nursing and Health Sciences, Hong Kong Metropolitan University , 1 Sheung Shing Street, Quarry Hill, Kowloon, 999077, Hong Kong ,","place":["China"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gregory Y H","family":"Lip","sequence":"additional","affiliation":[{"name":"Tianjin Key Laboratory of Ionic-Molecular Function of Cardiovascular Disease, Department of Cardiology, Tianjin Institute of Cardiology, Second Hospital of Tianjin Medical University , No. 23, Pingjiang Road, Hexi District, Tianjin 300211 ,","place":["China"]},{"name":"Liverpool Centre for Cardiovascular Science at University of Liverpool, Liverpool John Moores University and Liverpool Heart & Chest Hospital , 6 West Derby Street, L7 8TX, Liverpool ,","place":["United Kingdom"]},{"name":"Department of Clinical Medicine, Aalborg University , Fredrik Bajers Vej 7K, 9220, Aalborg ,","place":["Denmark"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kang-Yin","family":"Chen","sequence":"additional","affiliation":[{"name":"Tianjin Key Laboratory of Ionic-Molecular Function of Cardiovascular Disease, Department of Cardiology, Tianjin Institute of Cardiology, Second Hospital of Tianjin Medical University , No. 23, Pingjiang Road, Hexi District, Tianjin 300211 ,","place":["China"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0482-0738","authenticated-orcid":false,"given":"Tong","family":"Liu","sequence":"additional","affiliation":[{"name":"Tianjin Key Laboratory of Ionic-Molecular Function of Cardiovascular Disease, Department of Cardiology, Tianjin Institute of Cardiology, Second Hospital of Tianjin Medical University , No. 23, Pingjiang Road, Hexi District, Tianjin 300211 ,","place":["China"]}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"286","published-online":{"date-parts":[[2025,9,29]]},"reference":[{"key":"2026021707314960700_ref1","doi-asserted-by":"publisher","first-page":"2264","DOI":"10.1161\/circulationaha.111.019893","article-title":"Atrial fibrillation pathophysiology: implications for management","volume":"124","author":"Iwasaki","year":"2011","journal-title":"Circulation"},{"key":"2026021707314960700_ref2","doi-asserted-by":"publisher","first-page":"1950","DOI":"10.1001\/jama.2015.4369","article-title":"Stroke prevention in atrial fibrillation: a systematic review","volume":"313","author":"Lip","year":"2015","journal-title":"JAMA"},{"key":"2026021707314960700_ref3","doi-asserted-by":"publisher","first-page":"1965","DOI":"10.1093\/eurjpc\/zwad228","article-title":"Atrial fibrillation in embolic stroke of undetermined source: role of advanced imaging of left atrial function","volume":"30","author":"Chousou","year":"2023","journal-title":"Eur J Prev Cardiol"},{"key":"2026021707314960700_ref4","doi-asserted-by":"publisher","first-page":"1038","DOI":"10.1093\/eurheartj\/ehn579","article-title":"Atrial fibrillation in acute myocardial infarction: a systematic review of the incidence, clinical features and prognostic implications","volume":"30","author":"Schmitt","year":"2009","journal-title":"Eur Heart J"},{"key":"2026021707314960700_ref5","doi-asserted-by":"publisher","DOI":"10.1093\/ehjcvp\/pvae066","article-title":"Incidence and outcomes of transient new-onset atrial fibrillation complicating acute coronary syndromes: results from a systematic review and meta-analysis","author":"Salerno","year":"2025","journal-title":"Eur Heart J Cardiovasc Pharmacother"},{"key":"2026021707314960700_ref6","doi-asserted-by":"publisher","first-page":"125","DOI":"10.1016\/j.ijcard.2018.04.096","article-title":"Increased risk of ischemic stroke associated with new-onset atrial fibrillation complicating acute coronary syndrome: a systematic review and meta-analysis","volume":"265","author":"Luo","year":"2018","journal-title":"Int J Cardiol"},{"key":"2026021707314960700_ref7","doi-asserted-by":"publisher","first-page":"162","DOI":"10.1016\/j.ajem.2020.08.013","article-title":"Clinical outcome of new-onset atrial fibrillation after emergency percutaneous coronary intervention for myocardial infarction","volume":"45","author":"Zhou","year":"2021","journal-title":"Am J Emerg Med"},{"key":"2026021707314960700_ref8","doi-asserted-by":"publisher","DOI":"10.1016\/j.jjcc.2024.12.007","article-title":"The impact of new-onset atrial fibrillation in the setting of acute coronary syndrome","author":"Bazoukis","year":"2025","journal-title":"J Cardiol"},{"key":"2026021707314960700_ref9","doi-asserted-by":"publisher","first-page":"775","DOI":"10.1161\/circulationaha.118.036248","article-title":"Major bleeding rates in atrial fibrillation patients on single, dual, or triple antithrombotic therapy","volume":"139","author":"van Rein","year":"2019","journal-title":"Circulation"},{"key":"2026021707314960700_ref10","doi-asserted-by":"publisher","first-page":"260","DOI":"10.1378\/chest.09-3083","article-title":"\u201ctriple therapy\u201d rather than \u201ctriple threat\u201d: a meta-analysis of the two antithrombotic regimens after stent implantation in patients receiving long-term oral anticoagulant treatment","volume":"139","author":"Zhao","year":"2011","journal-title":"Chest"},{"key":"2026021707314960700_ref11","doi-asserted-by":"publisher","first-page":"1509","DOI":"10.1056\/NEJMoa1817083","article-title":"Antithrombotic therapy after acute coronary syndrome or PCI in atrial fibrillation","volume":"380","author":"Lopes","year":"2019","journal-title":"N Engl J Med"},{"key":"2026021707314960700_ref12","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1093\/europace\/euz259","article-title":"Revisiting the effects of omitting aspirin in combined antithrombotic therapies for atrial fibrillation and acute coronary syndromes or percutaneous coronary interventions: meta-analysis of pooled data from the PIONEER AF-PCI, RE-DUAL PCI, and AUGUSTUS trials","volume":"22","author":"Potpara","year":"2020","journal-title":"Europace"},{"key":"2026021707314960700_ref13","doi-asserted-by":"publisher","DOI":"10.1093\/eurheartj\/ehae176","article-title":"2024 ESC guidelines for the management of atrial fibrillation developed in collaboration with the European Association for Cardio-Thoracic Surgery (EACTS): developed by the task force for the management of atrial fibrillation of the European Society of Cardiology (ESC), with the special contribution of the European heart rhythm association (EHRA) of the ESC. Endorsed by the European stroke organisation (ESO)","author":"Van Gelder","year":"2024","journal-title":"Eur Heart J"},{"key":"2026021707314960700_ref14","doi-asserted-by":"publisher","first-page":"109","DOI":"10.1016\/j.jacc.2023.08.017","article-title":"2023 ACC\/AHA\/ACCP\/HRS guideline for the diagnosis and Management of Atrial Fibrillation: a report of the American College of Cardiology\/American Heart Association joint committee on clinical practice guidelines","volume":"83","author":"Joglar","year":"2024","journal-title":"J Am Coll Cardiol"},{"key":"2026021707314960700_ref15","doi-asserted-by":"publisher","first-page":"89","DOI":"10.1016\/j.ahj.2021.04.012","article-title":"Long-term prognostic outcomes and implication of oral anticoagulants in patients with new-onset atrial fibrillation following st-segment elevation myocardial infarction","volume":"238","author":"Madsen","year":"2021","journal-title":"Am Heart J"},{"key":"2026021707314960700_ref16","doi-asserted-by":"publisher","first-page":"189","DOI":"10.1093\/ehjcvp\/pvaa027","article-title":"Long-term prognosis of de novo atrial fibrillation during acute myocardial infarction: the impact of anti-thrombotic treatment strategies","volume":"7","author":"Hofer","year":"2021","journal-title":"Eur Heart J Cardiovasc Pharmacother"},{"key":"2026021707314960700_ref17","doi-asserted-by":"publisher","first-page":"e30","DOI":"10.1097\/mjt.0000000000000858","article-title":"Antithrombotic therapy and outcomes of patients with new-onset transient atrial fibrillation after ST-segment elevation myocardial infarction","volume":"28","author":"Kayapinar","year":"2021","journal-title":"Am J Ther"},{"key":"2026021707314960700_ref18","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1007\/s00392-011-0357-5","article-title":"The significance of new onset atrial fibrillation complicating acute myocardial infarction","volume":"101","author":"Zusman","year":"2012","journal-title":"Clin Res Cardiol"},{"key":"2026021707314960700_ref19","doi-asserted-by":"publisher","first-page":"1258536","DOI":"10.3389\/fmed.2023.1258536","article-title":"Real-world national trends and influencing factors preference of non-vitamin K antagonist oral anticoagulants in China","volume":"10","author":"Zhu","year":"2023","journal-title":"Front Med (Lausanne)"},{"key":"2026021707314960700_ref20","doi-asserted-by":"publisher","first-page":"10760296241271338","DOI":"10.1177\/10760296241271338","article-title":"Development and validation of a predictive model for intracranial haemorrhage in patients on direct oral anticoagulants","volume":"30","author":"Liu","year":"2024","journal-title":"Clin Appl Thromb Hemost"},{"key":"2026021707314960700_ref21","doi-asserted-by":"publisher","first-page":"20","DOI":"10.1056\/NEJMoa1817591","article-title":"Alcohol abstinence in drinkers with atrial fibrillation","volume":"382","author":"Voskoboinik","year":"2020","journal-title":"N Engl J Med"},{"key":"2026021707314960700_ref22","doi-asserted-by":"publisher","first-page":"692","DOI":"10.1111\/j.1538-7836.2005.01204.x","article-title":"Definition of major bleeding in clinical investigations of antihemostatic medicinal products in non-surgical patients","volume":"3","author":"Schulman","year":"2005","journal-title":"J Thromb Haemost"},{"key":"2026021707314960700_ref23","doi-asserted-by":"publisher","first-page":"117","DOI":"10.1007\/s40119-019-0136-3","article-title":"Adverse outcomes associated with pre-existing and new-onset atrial fibrillation in patients with acute coronary syndrome: a retrospective cohort study","volume":"8","author":"Wang","year":"2019","journal-title":"Cardiol Ther"},{"key":"2026021707314960700_ref24","doi-asserted-by":"publisher","first-page":"1587","DOI":"10.1161\/circulationaha.110.986661","article-title":"Mortality associated with atrial fibrillation in patients with myocardial infarction: a systematic review and meta-analysis","volume":"123","author":"Jabre","year":"2011","journal-title":"Circulation"},{"key":"2026021707314960700_ref25","doi-asserted-by":"publisher","first-page":"1046298","DOI":"10.3389\/fcvm.2022.1046298","article-title":"Oral anticoagulant therapy for patients with new-onset atrial fibrillation following acute myocardial infarction: a narrative review","volume":"9","author":"Yu","year":"2022","journal-title":"Front Cardiovasc Med"},{"key":"2026021707314960700_ref26","doi-asserted-by":"publisher","DOI":"10.3390\/jcm9051481","article-title":"Involvement of autonomic nervous system in new-onset atrial fibrillation during acute myocardial infarction","author":"Sagnard","year":"2020","journal-title":"J Clin Med"},{"key":"2026021707314960700_ref27","doi-asserted-by":"publisher","first-page":"132017","DOI":"10.1016\/j.ijcard.2024.132017","article-title":"Prognosis and antithrombotic practice patterns in patients with recurrent and transient atrial fibrillation following acute coronary syndrome: a nationwide study","volume":"407","author":"Petersen","year":"2024","journal-title":"Int J Cardiol"},{"key":"2026021707314960700_ref28","doi-asserted-by":"publisher","first-page":"1335","DOI":"10.1016\/s0140-6736(19)31872-0","article-title":"Edoxaban-based versus vitamin K antagonist-based antithrombotic regimen after successful coronary stenting in patients with atrial fibrillation (ENTRUST-AF PCI): a randomised, open-label, phase 3b trial","volume":"394","author":"Vranckx","year":"2019","journal-title":"Lancet"},{"key":"2026021707314960700_ref29","doi-asserted-by":"publisher","first-page":"616","DOI":"10.1016\/j.jacc.2015.05.062","article-title":"Use and outcomes of triple therapy among older patients with acute myocardial infarction and atrial fibrillation","volume":"66","author":"Hess","year":"2015","journal-title":"J Am Coll Cardiol"},{"key":"2026021707314960700_ref30","doi-asserted-by":"publisher","first-page":"422","DOI":"10.1055\/s-0040-1718729","article-title":"The east Asian paradox: an updated position statement on the challenges to the current antithrombotic strategy in patients with cardiovascular disease","volume":"121","author":"Kim","year":"2021","journal-title":"Thromb Haemost"},{"key":"2026021707314960700_ref31","doi-asserted-by":"publisher","first-page":"309","DOI":"10.1016\/j.jacc.2007.01.098","article-title":"Racial\/ethnic differences in the risk of intracranial hemorrhage among patients with atrial fibrillation","volume":"50","author":"Shen","year":"2007","journal-title":"J Am Coll Cardiol"},{"key":"2026021707314960700_ref32","doi-asserted-by":"publisher","first-page":"582","DOI":"10.1111\/j.1365-2125.2005.02361.x","article-title":"Is INR between 2.0 and 3.0 the optimal level for Chinese patients on warfarin therapy for moderate-intensity anticoagulation?","volume":"59","author":"You","year":"2005","journal-title":"Br J Clin Pharmacol"},{"key":"2026021707314960700_ref33","doi-asserted-by":"publisher","first-page":"169","DOI":"10.5853\/jos.2016.00052","article-title":"Asian patients with stroke plus atrial fibrillation and the dose of non-vitamin K oral anticoagulants","volume":"18","author":"Bang","year":"2016","journal-title":"J Stroke"},{"key":"2026021707314960700_ref34","doi-asserted-by":"publisher","first-page":"1909","DOI":"10.1056\/NEJMoa1007964","article-title":"Clopidogrel with or without omeprazole in coronary artery disease","volume":"363","author":"Bhatt","year":"2010","journal-title":"N Engl J Med"},{"key":"2026021707314960700_ref35","doi-asserted-by":"publisher","first-page":"1231","DOI":"10.1016\/j.amjmed.2022.05.031","article-title":"Association of antisecretory drugs with upper gastrointestinal bleeding in patients using oral anticoagulants: a systematic review and meta-analysis","volume":"135","author":"Kurlander","year":"2022","journal-title":"Am J Med"}],"container-title":["Postgraduate Medical Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/pmj\/article-pdf\/102\/1205\/271\/64427562\/qgaf163.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/pmj\/article-pdf\/102\/1205\/271\/64427562\/qgaf163.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,2,17]],"date-time":"2026-02-17T12:31:54Z","timestamp":1771331514000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/pmj\/article\/102\/1205\/271\/8267895"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,9,29]]},"references-count":35,"journal-issue":{"issue":"1205","published-online":{"date-parts":[[2025,9,29]]},"published-print":{"date-parts":[[2026,2,13]]}},"URL":"https:\/\/doi.org\/10.1093\/postmj\/qgaf163","relation":{},"ISSN":["0032-5473","1469-0756"],"issn-type":[{"value":"0032-5473","type":"print"},{"value":"1469-0756","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2026,3]]},"published":{"date-parts":[[2025,9,29]]}}}